Now we just need our stroke doctors and hospitals to contact researchers and get this tested in humans. Does your stroke hospital even follow stroke research?
Effect of Quercetin-Loaded Mesoporous Silica Nanoparticles on Myocardial Ischemia-Reperfusion Injury in Rats and Its Mechanism
Authors Liu CJ, Yao L, Hu YM, Zhao BT
Received 17 August 2020
Accepted for publication 10 November 2020
Published 2 February 2021 Volume 2021:16 Pages 741—752
DOI https://doi.org/10.2147/IJN.S277377
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Dr Linlin Sun
Chen-Jie Liu,1 Li Yao,2 Ya-Min Hu,2 Bo-Tao Zhao2
1ECG Room of Physical Examination Center of Cangzhou Central Hospital, Cangzhou, Hebei, 061001, People’s Republic of China; 2Six Cardiovascular Departments of Cangzhou Central Hospital, Cangzhou, Hebei, 061001, People’s Republic of China
Correspondence: Chen-Jie Liu
ECG
Room of Physical Examination Center of Cangzhou Central Hospital, No. 5
Guangrong Road, Canal District, Cangzhou, Hebei Province, 061001,
People’s Republic of China
Email liuchenjiecz@163.com
Background:
Quercetin has potential value in treating cardiovascular diseases, but
it is not suitable for clinical application due to its own water
solubility. The limitation of quercetin can be distinctly ameliorated by
delivering it with nanocarriers.
Objective: To
determine the effect of quercetin-loaded mesoporous silica nanoparticles
(Q-MSNs) on myocardial ischemia-reperfusion injury in rats and its
mechanism.
Methods: Q-MSNs were synthesized, and the
morphology of Q-MSNs and MSNs was characterized by transmission
electron microscopy and dynamic light scattering technique,
respectively. Healthy rats were enrolled and randomly divided into a
sham operation control group, an ischemia-reperfusion (IR) group, an
IR+Q group, an IR+Q-MSNs group, and an MSNs group (each n = 10). Rats in
the sham operation group were not treated with ischemia reperfusion,
but given normal perfusion meantime. Rats in the sham operation control
group, IR group, and MSNs group were given normal saline for 10 days
before ischemia reperfusion, and rats in the IR+Q group and IR+Q-MSNs
group were given drugs by gavage for 10 days before ischemia
reperfusion. Primary myocardial cells were sampled from SD neonatal rats
to construct hypoxia/reoxygenation myocardial cell models. The
myocardial cells were assigned to a control group, IR group, quercetin
(Q) group, Q-MSNs group, and MSNs group. Except for the control group,
all the other groups were treated with hypoxia/reoxygenation. Cells in
the Q group were treated with quercetin (10 μM, 20 μM, 40 μM) for 24 h
in advance and then treated with measures to cause hypoxia-reoxygenation
injury. Cells in the Q-MSNs group were treated with the same
concentration of loaded quercetin and the same method used for the Q
group. The myocardial apoptosis, myocardial infarction, ventricular
remodeling, hemodynamic indexes, physiological and biochemical indexes,
and JAK2/STAT3 pathway expression of each group were detected, and the
apoptosis, viability, oxidative stress, and JAK2/STAT3 pathway
expression of primary myocardial cells in each group were also detected.
Results:
Quercetin significantly activated the JAK2/STAT3 pathway in vivo and in
vitro, and MSNs intensified the activation. Compared with quercetin,
Q-MSNs were more effective in inhibiting cell apoptosis and oxidative
stress, reducing myocardial infarction size, improving ventricular
remodeling and cardiac function-related biochemical indexes, and
promoting the recovery of cardiac blood flow.
Conclusion:
Q-MSNs can significantly enhance the activation effect of quercetin on
JAK2/STAT3 pathway, thus enhancing its protection on the heart of MIRI
rats.
Keywords: myocardial ischemia-reperfusion
injury, quercetin-loaded mesoporous silica nanoparticles, JAK2/STAT3
pathway, cardiovascular diseases
No comments:
Post a Comment